Wall Street Zen Upgrades Praxis Precision Medicines (NASDAQ:PRAX) to “Hold”

Praxis Precision Medicines (NASDAQ:PRAX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

PRAX has been the topic of a number of other reports. Needham & Company LLC lifted their target price on shares of Praxis Precision Medicines from $575.00 to $582.00 and gave the stock a “buy” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $374.00 price target (down from $420.00) on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $462.00 price target (up from $449.00) on shares of Praxis Precision Medicines in a research report on Friday. Raymond James Financial started coverage on Praxis Precision Medicines in a report on Friday, April 10th. They issued a “strong-buy” rating and a $815.00 price objective on the stock. Finally, Oppenheimer reissued an “outperform” rating and set a $650.00 target price (down from $750.00) on shares of Praxis Precision Medicines in a research note on Tuesday, June 2nd. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $573.05.

Praxis Precision Medicines Price Performance

Shares of PRAX opened at $360.76 on Friday. Praxis Precision Medicines has a 52-week low of $37.19 and a 52-week high of $382.54. The company has a market capitalization of $10.07 billion, a PE ratio of -27.90 and a beta of 2.78. The stock has a fifty day simple moving average of $303.99 and a two-hundred day simple moving average of $315.78.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, topping the consensus estimate of ($3.67) by $0.80. As a group, equities analysts anticipate that Praxis Precision Medicines will post -14.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total value of $3,611,312.00. Following the completion of the transaction, the director directly owned 2,337 shares of the company’s stock, valued at $727,554.84. The trade was a 83.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is owned by company insiders.

Institutional Trading of Praxis Precision Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NBC Securities Inc. purchased a new position in shares of Praxis Precision Medicines in the fourth quarter valued at approximately $38,000. Parallel Advisors LLC grew its holdings in shares of Praxis Precision Medicines by 3,000.0% in the first quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock valued at $40,000 after purchasing an additional 120 shares in the last quarter. Danske Bank A S purchased a new stake in Praxis Precision Medicines during the 4th quarter worth approximately $59,000. Tower Research Capital LLC TRC increased its stake in Praxis Precision Medicines by 24.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock worth $77,000 after buying an additional 359 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in Praxis Precision Medicines by 60.0% during the 4th quarter. Farther Finance Advisors LLC now owns 368 shares of the company’s stock worth $108,000 after buying an additional 138 shares in the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: Praxis said it expects two FDA decisions within roughly six months and is targeting approximately $10 billion in peak sales for ulixacaltamide. The company is also preparing a commercial organization of about 300 field employees, signaling confidence in the drug’s market potential. Praxis signals two FDA decisions and targets $10 billion in peak sales
• Positive Sentiment: Management’s planned commercial launch could exceed expectations if regulatory approvals are secured and adoption develops as projected, strengthening the long-term growth narrative for PRAX. Praxis commercial launch could smash expectations
• Positive Sentiment: Praxis reported a second-quarter loss of $2.87 per share, narrower than the $3.67 analyst consensus, providing a better-than-expected earnings result. Needham & Company also raised its price target from $575 to $582 and maintained a Buy rating. Needham raises Praxis price target Praxis corporate update and second-quarter results
• Neutral Sentiment: The company remains unprofitable and expects a full-year loss, while building a sizeable commercial infrastructure ahead of potential approvals. Those investments could increase expenses before product revenue begins.
• Negative Sentiment: With PRAX near its 52-week high, a market capitalization above $10 billion, and a high beta, the stock is vulnerable to valuation-driven profit-taking. Investors may also be locking in gains while awaiting the FDA decisions and clearer evidence of launch execution.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.